Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma

Miiru Izumi, Yoichi Nakanishi, Ichiro Yoshino, Manabu Nakashima, Takeshi Watanabe, Nobuyuki Hara

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

BACKGROUND. RCAS1 is a recently discovered antigen molecule expressed on the membrane of cancer cells, and it acts as a ligand for a putative receptor present on immune cells such as T, B and NK cells. It has been suggested that RCAS1 expression is related to the escape of tumors from immune surveillance. In this study, the relation between RCAS1 expression and various clinicopathologic variables, including patient prognosis, was investigated in lung carcinoma through immunohistochemical analysis. METHODS, One hundred two surgically resected nonsmall cell lung carcinoma cases were examined histopathologically by means of the monoclonal antibody 22-1-1, which is specific for RCAS1. The correlation between RCAS1 expression and the clinicopathologic features of patients was evaluated. Moreover, the correlation between RCAS1 expression and the survival of patients was analyzed by the Kaplan-Meier method log-rank test, and multivariate analysis was performed by using the Cox proportional hazard model. RESULTS. The samples of 48 of the 102 lung carcinoma patients (47.1%) were positive for RCAS1. There were significant correlations between RCAS1 expression and either pathologic staging (P = 0.0003) or tumor differentiation (P = 0.0308). The survival time for the RCAS1-positive group was significantly shorter than that for RCAS1-negative group (P < 0.0001). Moreover, multivariate analysis for overall survival revealed that RCAS1 expression was a significantly independent prognostic factor in nonsmall cell lung carcinoma patients. CONCLUSION. These results suggested that RCAS1 expression may play an important role in the immune escape mechanism and that RCAS1 expression may be a good indicator of poor prognosis in patients with nonsmall cell lung carcinoma.

Original languageEnglish
Pages (from-to)446-451
Number of pages6
JournalCancer
Volume92
Issue number2
DOIs
Publication statusPublished - Jul 15 2001

Fingerprint

Neoplasm Antigens
Carcinoma
Lung
Survival
Multivariate Analysis
Tumor Escape
Proportional Hazards Models
Natural Killer Cells
Neoplasms
B-Lymphocytes
Monoclonal Antibodies
Cell Membrane
Ligands
T-Lymphocytes
Antigens

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. / Izumi, Miiru; Nakanishi, Yoichi; Yoshino, Ichiro; Nakashima, Manabu; Watanabe, Takeshi; Hara, Nobuyuki.

In: Cancer, Vol. 92, No. 2, 15.07.2001, p. 446-451.

Research output: Contribution to journalArticle

Izumi, Miiru ; Nakanishi, Yoichi ; Yoshino, Ichiro ; Nakashima, Manabu ; Watanabe, Takeshi ; Hara, Nobuyuki. / Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. In: Cancer. 2001 ; Vol. 92, No. 2. pp. 446-451.
@article{32235bbb8bf84f0094f2963b78206cc6,
title = "Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma",
abstract = "BACKGROUND. RCAS1 is a recently discovered antigen molecule expressed on the membrane of cancer cells, and it acts as a ligand for a putative receptor present on immune cells such as T, B and NK cells. It has been suggested that RCAS1 expression is related to the escape of tumors from immune surveillance. In this study, the relation between RCAS1 expression and various clinicopathologic variables, including patient prognosis, was investigated in lung carcinoma through immunohistochemical analysis. METHODS, One hundred two surgically resected nonsmall cell lung carcinoma cases were examined histopathologically by means of the monoclonal antibody 22-1-1, which is specific for RCAS1. The correlation between RCAS1 expression and the clinicopathologic features of patients was evaluated. Moreover, the correlation between RCAS1 expression and the survival of patients was analyzed by the Kaplan-Meier method log-rank test, and multivariate analysis was performed by using the Cox proportional hazard model. RESULTS. The samples of 48 of the 102 lung carcinoma patients (47.1{\%}) were positive for RCAS1. There were significant correlations between RCAS1 expression and either pathologic staging (P = 0.0003) or tumor differentiation (P = 0.0308). The survival time for the RCAS1-positive group was significantly shorter than that for RCAS1-negative group (P < 0.0001). Moreover, multivariate analysis for overall survival revealed that RCAS1 expression was a significantly independent prognostic factor in nonsmall cell lung carcinoma patients. CONCLUSION. These results suggested that RCAS1 expression may play an important role in the immune escape mechanism and that RCAS1 expression may be a good indicator of poor prognosis in patients with nonsmall cell lung carcinoma.",
author = "Miiru Izumi and Yoichi Nakanishi and Ichiro Yoshino and Manabu Nakashima and Takeshi Watanabe and Nobuyuki Hara",
year = "2001",
month = "7",
day = "15",
doi = "10.1002/1097-0142(20010715)92:2<446::AID-CNCR1341>3.0.CO;2-3",
language = "English",
volume = "92",
pages = "446--451",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma

AU - Izumi, Miiru

AU - Nakanishi, Yoichi

AU - Yoshino, Ichiro

AU - Nakashima, Manabu

AU - Watanabe, Takeshi

AU - Hara, Nobuyuki

PY - 2001/7/15

Y1 - 2001/7/15

N2 - BACKGROUND. RCAS1 is a recently discovered antigen molecule expressed on the membrane of cancer cells, and it acts as a ligand for a putative receptor present on immune cells such as T, B and NK cells. It has been suggested that RCAS1 expression is related to the escape of tumors from immune surveillance. In this study, the relation between RCAS1 expression and various clinicopathologic variables, including patient prognosis, was investigated in lung carcinoma through immunohistochemical analysis. METHODS, One hundred two surgically resected nonsmall cell lung carcinoma cases were examined histopathologically by means of the monoclonal antibody 22-1-1, which is specific for RCAS1. The correlation between RCAS1 expression and the clinicopathologic features of patients was evaluated. Moreover, the correlation between RCAS1 expression and the survival of patients was analyzed by the Kaplan-Meier method log-rank test, and multivariate analysis was performed by using the Cox proportional hazard model. RESULTS. The samples of 48 of the 102 lung carcinoma patients (47.1%) were positive for RCAS1. There were significant correlations between RCAS1 expression and either pathologic staging (P = 0.0003) or tumor differentiation (P = 0.0308). The survival time for the RCAS1-positive group was significantly shorter than that for RCAS1-negative group (P < 0.0001). Moreover, multivariate analysis for overall survival revealed that RCAS1 expression was a significantly independent prognostic factor in nonsmall cell lung carcinoma patients. CONCLUSION. These results suggested that RCAS1 expression may play an important role in the immune escape mechanism and that RCAS1 expression may be a good indicator of poor prognosis in patients with nonsmall cell lung carcinoma.

AB - BACKGROUND. RCAS1 is a recently discovered antigen molecule expressed on the membrane of cancer cells, and it acts as a ligand for a putative receptor present on immune cells such as T, B and NK cells. It has been suggested that RCAS1 expression is related to the escape of tumors from immune surveillance. In this study, the relation between RCAS1 expression and various clinicopathologic variables, including patient prognosis, was investigated in lung carcinoma through immunohistochemical analysis. METHODS, One hundred two surgically resected nonsmall cell lung carcinoma cases were examined histopathologically by means of the monoclonal antibody 22-1-1, which is specific for RCAS1. The correlation between RCAS1 expression and the clinicopathologic features of patients was evaluated. Moreover, the correlation between RCAS1 expression and the survival of patients was analyzed by the Kaplan-Meier method log-rank test, and multivariate analysis was performed by using the Cox proportional hazard model. RESULTS. The samples of 48 of the 102 lung carcinoma patients (47.1%) were positive for RCAS1. There were significant correlations between RCAS1 expression and either pathologic staging (P = 0.0003) or tumor differentiation (P = 0.0308). The survival time for the RCAS1-positive group was significantly shorter than that for RCAS1-negative group (P < 0.0001). Moreover, multivariate analysis for overall survival revealed that RCAS1 expression was a significantly independent prognostic factor in nonsmall cell lung carcinoma patients. CONCLUSION. These results suggested that RCAS1 expression may play an important role in the immune escape mechanism and that RCAS1 expression may be a good indicator of poor prognosis in patients with nonsmall cell lung carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0035878613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035878613&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010715)92:2<446::AID-CNCR1341>3.0.CO;2-3

DO - 10.1002/1097-0142(20010715)92:2<446::AID-CNCR1341>3.0.CO;2-3

M3 - Article

VL - 92

SP - 446

EP - 451

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -